Mobile

Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from AZT containing backbone to Truvada in HIV-1-in...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-005786-11

Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from AZT containing backbone to Truvada in HIV-1-infected patients on HAART (RECOMB Study)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To explore changes in limb fat assessed by DEXA measurements, after the substitution of the Zidovudine + Lamivudine NRTI-backbone by Truvada (TDF+FTC) versus maintaining the original Zidovudine-containing regimen without any change, through 48 wk.

Critère d'inclusion

  • Human Immunodeficiency Virus (HIV-1) Infection

Liens